MindBio Achieves Significant Product Development Milestone with up to 83% Accuracy in Intoxication Detection Using Voice Analytics and AI; Announces Private Placement
“Ultimately, our ambition is to make intoxication screening scalable and as simple as speaking into a device, transforming the economics of drug and alcohol testing while helping to prevent accidents, reduce injuries and save lives.”
VANCOUVER, British Columbia, Nov. 16, 2026 (GLOBE NEWSWIRE) -- MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) (the “Company” or “MindBio”), a biotechnology company advancing the commercialisation of AI-driven voice analytics for drug and alcohol intoxication detection, is pleased to announce that it is nearing final product testing for its first commercial pilot and is currently reporting up to 83% accuracy in intoxication detection under certain testing conditions.
The accuracy of MindBio’s prediction models with and without sober baseline tracking, in testing is now exceeding the accuracy of some commonly used commercially available cheek swab tests. This is the product development inflection point management has been working towards and marks a significant milestone in advancing a commercially viable product. Further extensive human testing is planned over the next 2-3 weeks before launching a first commercial pilot product.
The Company previously announced on October 14, 2026, the completion of manufacturing of its next-generation Edge AI Intoxication Detection Kiosk. Over the past six months, the Company has worked extensively with its team of scientists and engineers to refine and optimise its proprietary intoxication prediction models, with a particular focus on enhancing predictive accuracy, reliability and robustness. Shortly, the Company expects to launch the first commercially ready iteration of the product in Spanish language, bringing together its advanced Voice AI intoxication detection software and purpose-built hardware into a fully integrated system designed for commercial deployment.
Private Placement
The Company will conduct a non-brokered private placement (the “Offering”) of up to 3,888,889 units (each a “Unit”), at a price of $0.09 per Unit, for gross proceeds of up to CAD$350,000.
Each Unit will consist of one common share of the Company and one-half-of-one common share purchase warrant (each whole warrant, a “Warrant”.). Each whole Warrant will entitle the holder to purchase one common share of the Company at a price of $0.16 at any time on or before that date which is 36 months after the closing date of the Offering.
The proceeds from this private placement will be directed toward general working capital and funding the Company’s annual audit and legal expenses, OTC and CSE listing expenses.
Debt Conversion
The Company has also agreed to extinguish debt owed to an arms-length lender in the amount of CAD$38,000 into Units at $0.09 per Unit, for a total of 422,222 Units.
All securities issued in connection with the private placement and debt conversion will be subject to restrictions on resale for a period of four-months-and-one-day in accordance with applicable securities laws. Completion of the private placement and debt conversion remain subject to receipt of applicable regulatory approvals.
MindBio's Chief Executive Officer, Justin Hanka, commented:
“Achieving up to 83% accuracy in our recent product testing is an encouraging demonstration of the capability of our technology and the significant progress we have made over the past six months. We believe the human voice represents a largely untapped source of biological information, and our ability to harness that information using artificial intelligence presents a compelling commercial opportunity to reimagine how drug and alcohol intoxication screening is conducted globally.
We are now approaching an exciting inflection point for the Company as we transition from intensive research and development towards commercial deployment. Our immediate focus is on further improving predictive performance, demonstrating the technology in real-world operating environments and establishing a commercial pathway into industries where safety is paramount. Ultimately, our ambition is to make intoxication screening as simple as speaking into a device, transforming the economics of drug and alcohol testing while helping to prevent accidents, reduce injuries and save lives.”
For further information, please contact:
Justin Hanka, Chief Executive Officer
+61 433140886
justin@mindbiotherapeutics.com
www.mindbiotherapeutics.com
About MindBio Therapeutics Corp.
MindBio is a biotechnology company that is commercialising AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The AI prediction model analyses the human voice against millions of data points to detect drug and alcohol consumption. The Company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments including the mining industry, aviation, construction and law enforcement.
Cautionary Note Concerning Forward-Looking Statements:
The press release contains “forward-looking statements” within the meaning of applicable securities laws, including but not limited to, the Company’s ability to complete the Offering and option grants on the terms announced, and the development of its enterprise platform using voice and powered by AI for use in detecting drug and alcohol intoxication. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “budget,” “believe,” “project,” “estimate,” “expect,” “scheduled,” “forecast,” “strategy,” “future,” “likely,” “may,” “to be,” “could,” “would,” “should,” “will” and similar references to future periods or the negative or comparable terminology, as well as terms usually used in the future and conditional. Forward-looking statements are based on assumptions as of the date they are provided. However, there can be no assurance that such assumptions will reflect the actual outcome of such items or factors.
Additionally, there are known and unknown risk factors that could cause the Company’s actual results and financial conditions to differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important risk factors that could cause actual results and financial conditions to differ materially from those indicated in the forward-looking statements, include among others: the risk that the Company may not be able to raise the gross proceeds of the Offering; the failure to obtain the final regulatory approval; and technical challenges in the development or deployment of its enterprise platform; general economic, market and business conditions in Canada and Australia; market volatility; and unforeseen delays in timelines for any of the transactions or events described in this press release. All forward-looking information is qualified in its entirety by this cautionary statement.
The Company disclaims any obligation to revise or update any such forward-looking statement or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
Neither the Canadian Securities Exchange nor its Regulation Service Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of the information in this press release.
Latest Health & Supplement Reviews
- Neuro Energizer Reviews and Complaints 2026: How This Neuro-Sonic Breakthrough Is Reshaping Cognitive Therapy, Memory & Daily Focus
- Gluco6 Reviews and Complaints (March 2026) Real User Data on Natural Blood Sugar Balance and Glucose Stability
- Prime Biome Reviews (March 2026 Report) Doctor Explains Gut Skin Microbiome Reset And New Discoveries